Injectable division
CagriSema
AClass-leading
Novo Nordisk · certified
vs
Oral division
Orforglipron (Foundayo)
CompetitiveB
Eli Lilly · approved
17% · 8 pts more
Efficacy
9%
Mild (+2.3) · gentler
Tolerability
Notable (+7.6)
Subcutaneous injection
Route
Oral pill
None
Food / water rule
None
Refrigerated
Storage
Room temperature
The trade: Different divisions, so this is the trade, not a verdict. CagriSema loses about 8 more points of body weight. Orforglipron adds convenience: a daily pill instead of a once weekly injection, no cold chain, supply that scales. If maximum loss matters most and an injection is acceptable, CagriSema; if avoiding the needle matters more, Orforglipron.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Different divisions, so efficacy is shown as raw magnitude, not a verdict. The side marked leads or gentler wins that axis.
CagriSema verdict · Orforglipron verdict · Is the pill as good as the shot? · How this is scored